-->

Tag: precision oncology advancements

Home / precision oncology advancements

Categories

Sotorasib with panitumumab is approved by the USFDA for KRAS G12C-mutated colorectal cancer

On January 16, 2025, the Food and Drug Administration sanctioned the use of sotorasib (Lumakras, Amgen Inc.) in conjunction with panitumumab (Vectibix, Amgen Inc.) for adult patients diagnosed with KR...
precision-oncology-advancements

Encorafenib with cetuximab and mFOLFOX6 is approved by the USFDA for metastatic colorectal cancer with a BRAF V600E mutation

On December 20, 2024, the Food and Drug Administration conferred accelerated approval for encorafenib (Braftovi, Array BioPharma Inc., a subsidiary of Pfizer Inc.) in conjunction with cetuximab and mF...
precision-oncology-advancements

Scan the code